Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Takigawa, N, Kiura, K, Segawa, Y, Watanabe, Y, Kamei, H, Moritaka, T, Shibayama, T, Ueoka, H, Gemba, K, Yonei, T, Tabata, M, Shinkai, T, Hiraki, S, Takemoto, M, Kanazawa, S, Matsuo, K, Tanimoto, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360581/
https://www.ncbi.nlm.nih.gov/pubmed/17031394
http://dx.doi.org/10.1038/sj.bjc.6603422
_version_ 1782153084864036864
author Takigawa, N
Kiura, K
Segawa, Y
Watanabe, Y
Kamei, H
Moritaka, T
Shibayama, T
Ueoka, H
Gemba, K
Yonei, T
Tabata, M
Shinkai, T
Hiraki, S
Takemoto, M
Kanazawa, S
Matsuo, K
Tanimoto, M
author_facet Takigawa, N
Kiura, K
Segawa, Y
Watanabe, Y
Kamei, H
Moritaka, T
Shibayama, T
Ueoka, H
Gemba, K
Yonei, T
Tabata, M
Shinkai, T
Hiraki, S
Takemoto, M
Kanazawa, S
Matsuo, K
Tanimoto, M
author_sort Takigawa, N
collection PubMed
description Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0–4.9).
format Text
id pubmed-2360581
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23605812009-09-10 Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer Takigawa, N Kiura, K Segawa, Y Watanabe, Y Kamei, H Moritaka, T Shibayama, T Ueoka, H Gemba, K Yonei, T Tabata, M Shinkai, T Hiraki, S Takemoto, M Kanazawa, S Matsuo, K Tanimoto, M Br J Cancer Clinical Study Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0–4.9). Nature Publishing Group 2006-11-06 2006-10-10 /pmc/articles/PMC2360581/ /pubmed/17031394 http://dx.doi.org/10.1038/sj.bjc.6603422 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Takigawa, N
Kiura, K
Segawa, Y
Watanabe, Y
Kamei, H
Moritaka, T
Shibayama, T
Ueoka, H
Gemba, K
Yonei, T
Tabata, M
Shinkai, T
Hiraki, S
Takemoto, M
Kanazawa, S
Matsuo, K
Tanimoto, M
Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer
title Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer
title_full Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer
title_fullStr Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer
title_full_unstemmed Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer
title_short Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer
title_sort second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360581/
https://www.ncbi.nlm.nih.gov/pubmed/17031394
http://dx.doi.org/10.1038/sj.bjc.6603422
work_keys_str_mv AT takigawan secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT kiurak secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT segaway secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT watanabey secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT kameih secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT moritakat secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT shibayamat secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT ueokah secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT gembak secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT yoneit secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT tabatam secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT shinkait secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT hirakis secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT takemotom secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT kanazawas secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT matsuok secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer
AT tanimotom secondprimarycancerinsurvivorsfollowingconcurrentchemoradiationforlocallyadvancednonsmallcelllungcancer

Ejemplares similares